U.S. Markets open in 1 hr 12 mins

3 Biotech Stocks That Soared This Week: Are They Buys?

Keith Speights, The Motley Fool

Halloween week produced treats instead of tricks for some biotech investors. Quite a few biotech stocks rose by double-digit percentages, with three in particular soaring close to 30% and higher over the last five days.

Adamas Pharmaceuticals (NASDAQ: ADMS), Juno Therapeutics (NASDAQ: JUNO), and Stemline Therapeutics (NASDAQ: STML) ranked among the biggest biotech winners of the week. Here's what drove these stocks higher -- and whether or not they're smart picks now.

Businessman pointing to line charts going up

Image source: Getty Images.

Adamas Pharmaceuticals

Adamas Pharmaceuticals stock skyrocketed more than 40% this week, with two notable developments occurring. On Monday, Point72 Asset Management disclosed in an SEC filing that it had bought more shares of Adamas during the third quarter. That news caused Adamas stock to jump 21% in one day.

Three days later, Adamas provided an update on its third-quarter performance. Investors didn't care too much about the company's nearly non-existent revenue or its $23.4 million loss. Instead, there was growing excitement over Adamas' launch of Parkinson's disease drug Gocovri, which won U.S. Food and Drug Administration (FDA) approval on Aug. 24. 

Adamas announced that it had hired six regional sales managers for a planned sales force of 59 representatives. This sales team at least theoretically should have a relatively easy job promoting Gocovri, since it's the first and only drug approved by the FDA for treating dyskinesia (involuntary muscle movements) in patients with Parkinson's disease receiving levodopa-based therapy. 

Juno Therapeutics

Juno Therapeutics share price soared more than 30% higher this week. Like Adamas, Juno reported its third-quarter results. But that wasn't the big story for the biotech.

On Wednesday, Juno announced that it would present new data from its Transcend study of experimental drug JCAR017 in treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) at the American Society of Hematology (ASH) annual meeting in December. The biotech's sneak peek at the top-line data from the Transcend study gave investors plenty to like.

Patients taking JCAR017 had a three-month overall response rate of 80% and a complete response rate of 73%. Those impressive results were accompanied by a potentially better safety profile than the two CAR-T (chimeric antigen receptor T-cell) therapies that have already won approval.

Stemline Therapeutics

Stemline Therapeutics stock jumped close to 30% over the last week. The big gains came on Tuesday with Stemline's announcement of results from a phase 2 study of lead candidate SL-401 in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of acute myeloid leukemia (AML).

Patients in the third, pivotal stage of the clinical study who took SL-401 achieved a complete response rate of 54%. The overall response rate was 77%. In addition, 86% of patients with complete responses had no relapses at least five-to-eight months after initial treatment. 

Based on the success in the study, Stemline plans to begin submission of a Biologics License Application (BLA) by early 2018 at the latest. The company is also working with regulatory authorities to make SL-401 available to patients as quickly as possible under compassionate use provisions.

Are they buys?

Adamas is the only of these three biotechs to have already won FDA approval for a drug. That doesn't mean the stock isn't without significant risk, though. Adamas will probably have a slow launch for Gocovri as it builds its sales team and works through the payer reimbursement process. I think the stock should be a winner over the next several years, though. 

I'm bullish on Juno Therapeutics for a couple of reasons. First, the CAR-T space is hot right now, and the potential for JCAR017 looks really good. Second, Juno has a solid partnership with big biotech Celgene (NASDAQ: CELG). In fact, Celgene owns a nice chunk of Juno stock. It expects JCAR017 to be a blockbuster over the next several years. I do, too. 

Stemline Therapeutics also has plenty of room to grow, in my view. I suspect the chances for approval of SL-401 are pretty good. Treating BPDCN could be just the start for the drug. Stemline hopes for success in the broader AML indication as well.

But while I like the long-term prospects for all three biotech stocks, the decision about whether or not they're ones to buy now comes down to their cash positions. I'd hold off on buying Stemline for now, because I suspect the company will have to issue more stock in 2018 to raise cash. Adamas appears to be in good shape, though. And Juno has a great cash stockpile of more than $1 billion. My view is that Adamas and Juno are hot biotech stocks that should stay hot for a while.

More From The Motley Fool

Keith Speights owns shares of Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • SMART Global Holdings, Inc. (SGH) Dips More Than Broader Markets: What You Should Know
    Business
    Zacks

    SMART Global Holdings, Inc. (SGH) Dips More Than Broader Markets: What You Should Know

    SMART Global Holdings, Inc. (SGH) closed the most recent trading day at $29.12, moving -1.39% from the previous trading session. This has was narrower than the Computer and Technology sector's loss of 6.53% and the S&P 500's loss of 4.68% in that time. SGH will be looking to display strength as it nears its next earnings release, which is expected to be December 20, 2018.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It
    World
    Fortune

    China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It

    Later this week, the long-awaited 34-mile sea bridge connecting mainland China to Hong Kong and Macau will finally open. In a ceremony on Tuesday that Chinese president Xi Jinping will reportedly attend, the bridge will officially open. Some critics see the Hong Kong-Zhuhai-Macau Bridge as an attempt by mainland China to tighten its grip on Hong Kong, which is an autonomous region.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson
    News
    MarketWatch

    Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson

    October is living up to its infamous reputation as a volatile month for stocks with major indexes down sharply and there is likely more pain ahead for investors, according to one prominent Wall Street analyst. The recent rebound “was a dead cat bounce,” said Michael Wilson, an equity strategist at Morgan Stanley, in a report. After eking out gains last week, the S&P 500 (SPX) is trading below the 200 DMA of 2,768 Monday as stocks struggle for direction with third-quarter earnings cycle picking up pace.

  • Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business
    Business
    Motley Fool

    Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business

    Advanced Micro Devices (NASDAQ: AMD) CEO Lisa Su said earlier this year that the company plans to achieve "mid-single-digit server unit share" by the end of 2018. The chipmaker's server chip market share crossed 1% at the end of the second quarter. Mercury Research estimates that AMD now commands 1.3% of the server market as compared to just 0.5% earlier.

  • Business
    Benzinga

    Xerox Corporation's Q3 Earnings Preview

    On Tuesday, Xerox Corporation (NYSE: XRX) will release its latest earnings report. Benzinga's outlook for Xerox is included in the following report. Earnings and Revenue Based on Xerox management projections, analysts predict EPS of 78 cents on revenue

  • A North Carolina Police Officer Fatally Shot a Black Motorist During a Traffic Stop
    News
    Time

    A North Carolina Police Officer Fatally Shot a Black Motorist During a Traffic Stop

    The shooting happened Sunday afternoon, Stacy Drakeford, director of Washington police and fire services, said in a statement. Drakeford said after the car was stopped, the driver got out of his vehicle with a gun. The officer then shot the man, who was identified as Cedric Pritchard of Washington.

  • Shares of downtrodden IBM 'ready to roar higher': Charts
    Business
    CNBC Videos

    Shares of downtrodden IBM 'ready to roar higher': Charts

    Jim Cramer and technician Larry Williams inspect the charts of IBM, which seem to show the beleaguered tech stock on the cusp of a rally.

  • Is the New Energy Transfer LP a Buy?
    Finance
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • Scana Drops Most Since 1987 on Concern Over Nuclear Costs
    Business
    Bloomberg

    Scana Drops Most Since 1987 on Concern Over Nuclear Costs

    South Carolina Circuit Judge John C. Hayes III is asking lawyers to submit orders regarding the constitutionality of the 2007 Base Load Review Act, which lets the utility charge customers for a pair of unfinished nuclear reactors, Scana said in a statement Monday. The South Carolina-based Post and Courier newspaper reported Monday that the judge is leaning toward ruling the law is unconstitutional, citing two unidentified people. The decision may threaten Dominion Energy Inc.’s planned $7.9 billion acquisition of the troubled utility.

  • Technology
    Benzinga

    Upcoming Earnings: Telecom Giants Verizon And AT&T Report This Week

    Two of the biggest telecom companies, Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T), are scheduled to report earnings this week. VZ is expected to report adjusted EPS of $1.19 on revenue of $32.51 billion, according to third-party consensus analyst expectations.

  • Saudi Arabia conference site hacked with disturbing image of murdered journalist Jamal Khashoggi
    World
    The Independent

    Saudi Arabia conference site hacked with disturbing image of murdered journalist Jamal Khashoggi

    Hackers have hijacked the website of a major conference in Saudi Arabia and placed an image of the murdered journalist Jamal Khashoggi on its homepage. The conference, dubbed “Davos in the Desert”, is due to take place this week in Riyadh but has been overshadowed by the withdrawal of several high-profile attendees over the murder of the Saudi dissident. The second annual Future Investment Initiative conference has billed itself as “a blueprint for the 22nd century” that is bringing together “the world’s most visionary and influential leaders in business, government and civil society”.

  • Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today
    Business
    Motley Fool

    Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today

    Canadian pot stocks are getting hit hard across the board today. As of 1:21 p.m. EDT, for example, shares of Canopy Growth Corporation (NYSE: CGC) and Cronos Group (NASDAQ: CRON) were both down by 11.2%, whereas Tilray's(NASDAQ: TLRY) stock had fallen by 14.4%. Canopy, Cronos, and Tilray all seem to be succumbing to a so-called "sell the news" event.

  • 2 Things to Watch When Ford Motor Company Reports Earnings
    Business
    Motley Fool

    2 Things to Watch When Ford Motor Company Reports Earnings

    Wall Street analysts expect Ford's earnings to fall from the third quarter of 2017. Ford has refreshed the Explorer twice since its 2011 debut, but its age is hurting Ford's pricing power. 1. How soon will Ford's new products arrive?

  • 5 Popular Marijuana Stocks I Wouldn't Buy With Free Money
    Business
    Motley Fool

    5 Popular Marijuana Stocks I Wouldn't Buy With Free Money

    Last week on Oct. 17, Canada lifted the curtain on nine decades of prohibition and legalized recreational marijuana for adults. Given the notable surge in pot stocks since the beginning of 2016, it's pretty evident that Wall Street and investors expect the industry to be a resounding success. With that being said, there are a handful of marijuana stocks -- some quite popular -- that I simply wouldn't buy, even if I were given free money to do so.

  • Business
    Benzinga

    Caterpillar Q3 Earnings Preview

    Caterpillar, Inc. (NYSE: CAT) unveils its next round of earnings this Tuesday. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement Earnings and Revenue Sell-side analysts expect Caterpillar's EPS to be near $2.83 on sales

  • Finance
    Investopedia

    The Berkshire Hathaway of Pot Will Begin Trading on the NYSE Tuesday

    Aurora Cannabis Inc. ( ACB) has confirmed that its shares will begin trading on the New York Stock Exchange (NYSE) Oct. 23. The Edmonton, Canada-based company, referred to in some circles as the Berkshire Hathaway Inc. ( BRK.B) of cannabis because of its successful track record investing in other firms, said its shares will trade under the ticker “ACB,” the same symbol it uses in its separate Toronto Stock Exchange listing. Aurora will become the third licensed Canadian cannabis company to list in the U.S. after Canopy Growth Corp. ( CGC) and Tilray Inc. ( TLRY).

  • Why Did AMD Stock Fall 25% in the First 20 Days of October?
    Finance
    Market Realist

    Why Did AMD Stock Fall 25% in the First 20 Days of October?

    October Has Been Weak for AMD Stock: What's Ahead? (Continued from Prior Part) AMD stock reacts to the market sell-off This year has been slow for semiconductor stocks due to growing trade tensions between the United States and China. The stock

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • Aurora Cannabis is plunging ahead of its debut on the New York Stock Exchange
    Business
    Business Insider

    Aurora Cannabis is plunging ahead of its debut on the New York Stock Exchange

    Aurora Cannabis is set to begin trading on the New York Stock Exchange on Tuesday under the ticker ACB. Aurora Cannabis was plunging Monday, down more than 14%, one day ahead of the company's trading debut on the New York Stock Exchange. The Canadian producer, which grows cannabis for both the adult-use and medicinal market, has seen its market capitalization explode by more than 150% since August — to nearly $10 billion — as both corporate giants and investors have gotten in on the "green rush" into marijuana.